Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
EVAX Stock Chart & Stats
$3.17
-$0.02(-2.40%)
At close: 4:00 PM EST
$3.17
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$1.20 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)53.77K
Market Cap
$20.02M
Enterprise Value$8.76M
Total Cash (Recent Filing)$10.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 05, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding6,316,572
10 Day Avg. Volume18,352
30 Day Avg. Volume53,773
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.75
Price to Sales (P/S)1.36
P/FCF Ratio-0.35
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue1.14
Enterprise Value/Gross Profit1.14
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$11.75Price Target Upside270.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$6.10M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyFollow‑up clinical data for EVX‑01 in advanced melanoma demonstrated strong, durable patient responses and sustained immune activation, supporting the vaccine's therapeutic potential.
Licensing And FundingA partner's in‑license exercise and licensing payment combined with capital raises have extended the company's operational runway and signaled external commercial interest.
Technology AdvantageThe proprietary AI‑Immunology platform identifies vaccine targets faster and at a fraction of the cost of traditional methods, potentially accelerating pipeline progression and lowering research expenses.
Bears Say
Competitive And Intellectual Property RiskCompetition from other immuno‑oncology approaches and potential intellectual‑property disputes could restrict market access and diminish future licensing opportunities.
Regulatory And Clinical Execution RiskMultiple clinical and regulatory hurdles remain for novel vaccine candidates, and setbacks in trials or approvals could delay development timelines and reduce investor confidence.
Scalability ChallengesPersonalized neoantigen vaccine production faces scaling and manufacturing constraints compared with small‑molecule platforms, which could limit commercial reach and raise per‑patient costs.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech’s price range in the past 12 months?
Evaxion Biotech lowest stock price was $1.20 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech’s market cap?
Evaxion Biotech’s market cap is $20.02M.
When is Evaxion Biotech’s upcoming earnings report date?
Evaxion Biotech’s upcoming earnings report date is Mar 05, 2026 which is tomorrow.
How were Evaxion Biotech’s earnings last quarter?
Evaxion Biotech released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.02.
Is Evaxion Biotech overvalued?
According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued.
Does Evaxion Biotech pay dividends?
Evaxion Biotech does not currently pay dividends.
What is Evaxion Biotech’s EPS estimate?
Evaxion Biotech’s EPS estimate is -0.3.
How many shares outstanding does Evaxion Biotech have?
Evaxion Biotech has 6,316,572 shares outstanding.
What happened to Evaxion Biotech’s price movement after its last earnings report?
Evaxion Biotech reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10.601%.
Which hedge fund is a major shareholder of Evaxion Biotech?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evaxion Biotech
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and significant advancements in R&D, including a transformative deal with MSD and promising clinical data for EVX-01. However, market uncertainties and extended evaluation periods for deals, like EVX-B2, present challenges. Overall, the achievements and financial stability significantly outweigh the challenges.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$11.75
▲(270.66% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.90% Other Institutional Investors
98.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---